For the first two months of this year, revenues from sales increased by 8% compared to the same period of 2016, including 5% decrease of domestic sales and 16% increase of export sales.
“We are very pleased with the results on the Russian market from the begining of this year and the trend is strenghtening in February reaching 40% increase in export sales.
We are hopeful also with regards to the registration of our product Tabex in the USA. After the news about the merger of Achieve and OncoGenex the good news continue. You can read more abou the cooperation of Achieve with NIH here:www.oncogenex.com.
The preliminary consolidated report of Sopharma Group for 2016 shows that even though the period was relatively difficult on our foreign markets, we still managed to reach a satisfactory EBITDA of 70 million BGN and a net profit of a little bit more than 50 million BGN. Analysis of the main indicators shows improved profitability due to optimization of main expenses and in the light of a maximum market price of a bit over 3 BGN for the year P/E is 8.31 and ROE is 10.9% compared to 5.3% for 2015.”, says Mr. Ognian Donev, PhD, CEO and Chairman of the Board of directors of Sopharma AD.